The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway

[1]  F. Hsieh,et al.  Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. , 2001, Gynecologic oncology.

[2]  S. Jee,et al.  Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency , 2001, Oncogene.

[3]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[4]  R. Bataille,et al.  IL‐6 up‐regulates Mcl‐1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathway , 1999, European journal of immunology.

[5]  R. Bataille,et al.  Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells , 1999, British journal of haematology.

[6]  H. Richter,et al.  The association of interleukin 6 with clinical and laboratory parameters of acute pelvic inflammatory disease. , 1999, American journal of obstetrics and gynecology.

[7]  M. Kuo,et al.  Interleukin-6 Inhibits Transforming Growth Factor-β-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Akt and Signal Transducers and Activators of Transcription 3 Pathways* , 1999, The Journal of Biological Chemistry.

[8]  S. Wiese,et al.  Developmental Requirement of gp130 Signaling in Neuronal Survival and Astrocyte Differentiation , 1999, The Journal of Neuroscience.

[9]  T. Out,et al.  Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. , 1999, Gynecologic oncology.

[10]  M. Kuo,et al.  Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis. , 1999, Molecular pharmacology.

[11]  Marcos González,et al.  Expression of Bcl‐2 by human bone marrow mast cells and its overexpression in mast cell leukemia , 1999, American journal of hematology.

[12]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[13]  T. Tlsty.  A molecular blueprint for targeting cancer? , 1999, Nature Genetics.

[14]  A. Klippel,et al.  Activation of Phosphatidylinositol 3-Kinase Is Sufficient for Cell Cycle Entry and Promotes Cellular Changes Characteristic of Oncogenic Transformation , 1998, Molecular and Cellular Biology.

[15]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[16]  M. Kuo,et al.  mcl-1 Is an Immediate-Early Gene Activated by the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Signaling Pathway and Is One Component of the GM-CSF Viability Response , 1998, Molecular and Cellular Biology.

[17]  T. Chard,et al.  Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. , 1998, British Journal of Cancer.

[18]  H. Kung,et al.  Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Chao,et al.  BCL-2 family: regulators of cell death. , 1998, Annual review of immunology.

[20]  P. Musiani,et al.  Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. , 1997, British Journal of Cancer.

[21]  R. Craig,et al.  Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. , 1997, Blood.

[22]  T. Hirano,et al.  A central role for Stat3 in IL‐6‐induced regulation of growth and differentiation in M1 leukemia cells. , 1996, The EMBO journal.

[23]  D. Hicks,et al.  Differential Growth Inhibition by the Aspirin Metabolite Salicylate in Human Colorectal Tumor Cell Lines: Enhanced Apoptosis in Carcinoma and in Vitro-transformed Adenoma Relative to Adenoma Cell Lines , 1996 .

[24]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[25]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[26]  C. Thompson,et al.  Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. , 1995, Cancer research.

[27]  R. Gascoyne,et al.  Short Communication Immunohistochemical Analysis of Mci-1 Protein in Human Tissues Differential Regulation of Mcl- 1 and Bcl-2 Protein Production Suggests a Unique Role for Mcl- 1 in Control of Programmed Cell Death In Vivo , 2007 .

[28]  P. Brousset,et al.  High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. , 1995, Blood.

[29]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[30]  R. Craig,et al.  The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2 , 1995, The Journal of cell biology.

[31]  P. Sparén,et al.  Strategies for global control of cervical cancer , 1995, International journal of cancer.

[32]  R. Craig,et al.  Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. , 1994, Cancer research.

[33]  E. Tartour,et al.  Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. , 1994, Cancer research.

[34]  R. Gascoyne,et al.  Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. , 1994, The American journal of pathology.

[35]  E. Heyderman,et al.  Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. , 1993, Gynecologic oncology.

[36]  R. Craig,et al.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Bast,et al.  Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. , 1992, American journal of obstetrics and gynecology.

[38]  S. Pinion,et al.  Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of cervix , 1991, The Lancet.

[39]  Masahiro Yamamoto,et al.  Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas , 1989, FEBS letters.

[40]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[41]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.